Current Report Filing (8-k)
23 Dezember 2020 - 2:30PM
Edgar (US Regulatory)
United
States
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 17, 2020
CHINA
JO-JO DRUGSTORES, INC.
(Exact
name of Company as specified in charter)
|
Nevada
|
|
001-34711
|
|
98-0557852
|
(State
or other jurisdiction
of Incorporation)
|
|
(Commission
File No.)
|
|
(IRS
Employer
Identification No.)
|
Hai
Wai Hai Tongxin Mansion Floor 6 Gong Shu District,
Hangzhou
City, Zhejiang Province, People’s Republic of China, 310008
(Address
of principal executive offices) (Zip Code)
Company’s
telephone number, including area code: +86-571-88219579
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under
any of the following provisions:
|
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
|
Common
Stock
|
|
CJJD
|
|
NASDAQ
Capital Market
|
Indicate
by check mark whether the Company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item
3.01
|
Notice
of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
|
Regaining
NASDAQ Continued Listing Compliance
As
previously disclosed, on October 16, 2020, China Jo-Jo Drugstores, Inc. (the “Company”) received a letter from The
Nasdaq Stock Exchange (“NASDAQ”) regarding the Company’s failure to comply with NASDAQ Continued Listing Rule
(“Rule”) 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.
On
December 17, 2020, NASDAQ notified the Company that it has determined that from November 18 to December 14, 2020, the closing
bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance
with Rule 5550(a)(2).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
CHINA
JO-JO DRUGSTORES, INC.
|
|
|
|
|
|
Date:
December 23, 2020
|
By:
|
/s/
Ming Zhao
|
|
|
Name:
|
Ming
Zhao
|
|
|
Title:
|
Chief
Financial Officer
|
2
China Jo Jo Drugstores (NASDAQ:CJJD)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
China Jo Jo Drugstores (NASDAQ:CJJD)
Historical Stock Chart
Von Jan 2024 bis Jan 2025
